Andrew T. Wilkins

Andrew is a partner in Cooley’s patent counseling and prosecution group, where he brings deep technical experience and strategic insight to clients across the biotechnology sector. With a practice focused on patent law for cutting-edge life sciences innovations, Andrew advises companies and investors on global patent portfolio development, life cycle management, IP due diligence and post-grant proceedings.

Andrew’s work spans a spectrum of advanced biotechnologies, including therapeutic antibodies and antibody-like molecules targeting oncology, autoimmune, cardiovascular and infectious diseases. He has extensive experience with immunotherapy platforms, such as CAR-T cells, recombinant T cell receptors (TCRs), peptide-based vaccines and immune checkpoint inhibitors. His technical fluency includes antibody and TCR engineering, Fc glycoengineering, viral delivery systems (lentiviral and adenoviral-associated virus vectors), gene therapy (replacement and editing), nanoparticle liposomes, RNA interference (RNAi) technologies and drug screening assays. He also advises on Bayh-Dole compliance for IP arising from National Institutes of Health-funded research.

With a strong foundation in academic and industrial research, Andrew previously served as an instructor in medicine at Harvard Medical School/Beth Israel Deaconess Medical Center and held research roles at GlaxoSmithKline, MRC Laboratory of Molecular Biology and Celltech. He has authored numerous peer-reviewed publications in leading journals, underscoring his ability to translate complex science into strategic IP protection.